Insights - Arrowhead Research (ARWR) presented on Friday at Biocentury’s Newsmakers in the Biotech Industry conference. Investors are paying close attention given an important data event in November for ARC-520 … Continue Reading
Read nowInsights - Following a teleconference with the FDA, AcelRx Pharmaceuticals (ACRX) says that a resubmission of the Zalviso New Drug Application won’t occur until the first quarter … Continue Reading
Read nowInsights - Acorda Therapeutics (NASDAQ:ACOR) will acquire privately-held Civitas Therapeutics for $525 million in cash, adding the phase 3-ready treatment for OFF episodes in Parkinson’s Disease (PD), CVT-301, to its roster … Continue Reading
Read nowInsights - A phase 3 trial of Threshold Pharma’s (THLD) hypoxia-targeting therapeutic, TH-302, in soft-tissue sarcoma will continue as planned following an interim analysis of the ongoing … Continue Reading
Read nowResearch - Arrowhead Research (ARWR) is a name we’ve been stalking since the company released initial data from a phase 2a study of ARC-520, a candidate for the treatment of hepatitis B infection.
PremiumInsights - Avanir Pharmaceuticals (AVNR) added $400 million to its valuation on Monday morning with positive results from a phase 2 trial evaluating the safety and efficacy of AVP-923 in Alzheimer’s … Continue Reading
Read nowInsights - Hyperion Therapeutics (HPTX) shuttered development of DiaPep277 in newly diagnosed Type 1 diabetes on Monday, citing improper trial conduct from the drug’s original developer, Andromeda Biotech. Hyperion acquired … Continue Reading
Read now
